Truist on Exelixis (EXEL): 'STELLAR-303 Unlikely To Drive Broad Adoption'

October 20, 2025 8:27 AM EDT Send to a Friend
Truist Securities analyst Asthika Goonewardene reiterated a Buy rating and $49.00 price target on Exelixis (NASDAQ: EXEL).The analyst commented: "STELLAR-303 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login